Brokerages Set Vericel Co. (NASDAQ:VCEL) PT at $46.40

Vericel Co. (NASDAQ:VCEL) has earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $46.40.

VCEL has been the topic of a number of recent analyst reports. TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a research report on Monday, January 29th. HC Wainwright lifted their price target on Vericel from $46.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Truist Financial reissued a “buy” rating and set a $54.00 price objective on shares of Vericel in a report on Tuesday, March 26th.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $44.67, for a total transaction of $781,725.00. Following the completion of the transaction, the chief executive officer now owns 194,870 shares of the company’s stock, valued at $8,704,842.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Vericel news, COO Michael Halpin sold 7,874 shares of Vericel stock in a transaction on Monday, March 11th. The stock was sold at an average price of $44.71, for a total transaction of $352,046.54. Following the completion of the transaction, the chief operating officer now owns 949 shares in the company, valued at $42,429.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $44.67, for a total value of $781,725.00. Following the completion of the sale, the chief executive officer now directly owns 194,870 shares in the company, valued at $8,704,842.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,267 shares of company stock valued at $2,450,996. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vericel

Several institutional investors and hedge funds have recently made changes to their positions in VCEL. Knights of Columbus Asset Advisors LLC boosted its holdings in Vericel by 98.5% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 226,015 shares of the biotechnology company’s stock worth $8,048,000 after purchasing an additional 112,169 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Vericel by 21.2% in the fourth quarter. Federated Hermes Inc. now owns 560,419 shares of the biotechnology company’s stock worth $19,957,000 after acquiring an additional 97,952 shares during the period. Envestnet Asset Management Inc. increased its position in Vericel by 54.4% during the third quarter. Envestnet Asset Management Inc. now owns 126,383 shares of the biotechnology company’s stock valued at $4,236,000 after acquiring an additional 44,507 shares during the last quarter. Legato Capital Management LLC lifted its holdings in Vericel by 20.6% in the fourth quarter. Legato Capital Management LLC now owns 10,340 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 1,765 shares during the period. Finally, Conestoga Capital Advisors LLC grew its stake in shares of Vericel by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company’s stock valued at $83,326,000 after purchasing an additional 109,215 shares during the period.

Vericel Stock Performance

Shares of VCEL opened at $47.83 on Friday. The firm has a market cap of $2.31 billion, a P/E ratio of -531.39 and a beta of 1.74. Vericel has a fifty-two week low of $30.18 and a fifty-two week high of $53.05. The business has a 50-day moving average of $47.24 and a 200 day moving average of $41.36.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.08. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $64.28 million. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. Vericel’s revenue was up 23.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.12 EPS. As a group, research analysts predict that Vericel will post 0.09 earnings per share for the current fiscal year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.